Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Role of Mms22p in DNA Damage Response in Candida albicans.
Yan L, Xiong J, Lu H, Lv QZ, Ma QY, Côte P, Whiteway M, Jiang YY. Yan L, et al. Among authors: cote p. G3 (Bethesda). 2015 Oct 4;5(12):2567-78. doi: 10.1534/g3.115.021840. G3 (Bethesda). 2015. PMID: 26438292 Free PMC article.
Chemogenomic Profiling of the Fungal Pathogen Candida albicans.
Chen Y, Mallick J, Maqnas A, Sun Y, Choudhury BI, Côte P, Yan L, Ni TJ, Li Y, Zhang D, Rodríguez-Ortiz R, Lv QZ, Jiang YY, Whiteway M. Chen Y, et al. Among authors: cote p. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02365-17. doi: 10.1128/AAC.02365-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29203491 Free PMC article.
Erratum for Chen et al., "Chemogenomic Profiling of the Fungal Pathogen Candida albicans".
Chen Y, Mallick J, Maqnas A, Sun Y, Choudhury BI, Côte P, Yan L, Ni TJ, Li Y, Zhang D, Rodríguez-Ortiz R, Lv QZ, Jiang YY, Whiteway M. Chen Y, et al. Among authors: cote p. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e00375-18. doi: 10.1128/AAC.00375-18. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29588354 Free PMC article. No abstract available.
Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection.
Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, Baril JG, Dion H, Lefebvre E, Thomas R, Côté P, Lapointe N, Routy JP, Sékaly RP, Conway B, Bernard NF. Alter G, et al. Among authors: cote p. J Immunol. 2003 Jul 1;171(1):477-88. doi: 10.4049/jimmunol.171.1.477. J Immunol. 2003. PMID: 12817033
696 results